Araştırma Makalesi
BibTex RIS Kaynak Göster

Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment

Yıl 2018, Cilt: 9 Sayı: 3, 173 - 178, 30.09.2018
https://doi.org/10.18663/tjcl.432886

Öz

Aim: Beside efficacy of the shock wave
lithotripsy (SWL) procedure, also its negative effects on the kidneys, its relation
with the oxidant/antioxidant balance and the search after biomarkers for the
detection of this negative effect gained interest in the recent years. The aim
of the study is to investigate the possible usage of  total antioxidant status (TAS), total oxidant
status (TOS), oxidative stress index (OSI), Paraoxonase-1    (PON-1) and Interleukin 6 (IL-6) parameters
as biomarkers for renal injury/trauma  in
the early period by patients undergoing SWL due to kidney stones.



Material
and Methods:
Forty patients receiving SWL therapy due to kidney stones were
included to study by collecting their blood samples
before and 2 hours after the procedure.



Results: It was observed that SWL therapy has
deteriorated the oxidant/antioxidant balance in terms of the oxidants by analyzing
the increase of IL-6 (
P <0,01) and
decrease in PON-1 (
P = 0.049). There
was no change observed in TAS (
P =
0.178) and TOS (
P = 0.175) and OSI (P = 0.551) parameters.



Conclusion:
This has shown
that IL-6 and PON-1 may be more sensitive markers of renal injury after SWL in
early period.

Kaynakça

  • 1. Silay MS, Ellison JS, Tailly T, Caione P. Update on Urinary Stones in Children: Current and Future Concepts in Surgical Treatment and Shockwave Lithotripsy. Eur Urol Focus. 2017; 9: 2405-4569.
  • 2. Rajiv G, Deepak D, Naval K et al. Does the type of steinstrasse predict the outcome of expectant therapy? Indian J Urol 2006; 22: 135.
  • 3. Platonov MA, Gillis AM, Kavanagh KM. Pacemakers, implantable cardioverter/defibrillators, and extracorporeal shockwave lithotripsy: evidence-based guidelines for the modern era. J Endourol 2008; 22: 243.
  • 4. Aksoy H, Aksoy Y, Turhan H, Keleş S, Ziypak T, Ozbey I. The effect of shock wave lithotripsy on nitric oxide and malondialdehyde levels in plasma and urine samples. Cell Biochem Funct 2007; 25: 533–36.
  • 5. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 2004; 286: 431-44.
  • 6. Dundar M, Kocak I, Yenisey C, Serter M, Ozeren B. Urinary and serum cytokine levels in patients undergoing SWL. BJU 2001; 27: 495–99.
  • 7. Chawla LS, Seneff MG, Nelson DR, Williams M, Levy H, Kimmel PL. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol 2007; 2: 22-30.
  • 8. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: The hunt goes on. Biochemical Pharmacology 2011; 81: 337-44.
  • 9. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112–19.
  • 10. Barbosa PV, Makhlouf AA, Thorner D, Ugarte R, Monga M. Shockwave lithotripsy is associated with a higher prevalence of hypertension. Urology. 2011; 78: 22-25.
  • 11. Fischer C, Wöhrle J, Pastor J, Morgenroth K, Senge T. Extracorporeal shockwave lithotripsy induced ultrastructural changes to the renal parenchyma under aspirin use. Electron microscopic findings in the rat kidney. Urologea 2007; 46: 150–55.
  • 12. Lingeman JE, Woods J, Toth PD, Evan AP, McAteer JA. The role of lithotripsy and its side effects. J Urol 1989; 141: 793–77.
  • 13. Clark DL, Connors BA, Evan AP, Willis LR, Handa RK, Gao S. Localization of renal oxidative stress and inflammatory response after lithotripsy. BJU Int 2009; 103: 1562–68.
  • 14. Li X, He D, Zhang L, Cheng X, Sheng B, Luo Y. A novel antioxidant agent, astragalosides, prevents shock wave-induced renal oxidative injury in rabbits. Urol Res 2006; 34: 277–82.
  • 15. Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 503–8.
  • 16. Tappel AI. Lipid Peroxidation damage to cell components. J Fed Proc 1993; 32: 1870-74.
  • 17. Yilmaz E, Haciislamoglu A, Kisa U, Dogan O, Yuvanc E, Batislam E. Ways in which SWL affects oxidant/antioxidant balance. Urolithiasis 2013; 41: 137-41.
  • 18. Goktas C ,Coskun A, Bicik Z et al. Evaluating ESWL-induced renal injury based on urinary TNF-α, IL-1α, and IL-6 levels Urol Res 2012; 40: 569–73.
  • 19. Nakazawa H, Genka C, Fujishima M. Pathological aspects of active oxygens/free radicals. Jpn J Physiol 1996; 46: 15–32.
  • 20. Dennen P, Altmann C, Kaufman J et al. Urine interleukin-6 is an early biomarker of acute kidney injury in children undergoing cardiac surgery Critical Care 2010; 14: 181.
  • 21. Rieder JM, Nisbet AA, Lesser T et al. IL-6 does not predict current urolithiasis in stone formers. J Endourol 2008; 22: 2373–75.
  • 22. Rhee E, Santiago L, Park E, Lad P, Bellman GC. Urinary IL-6 is elevated in patients with urolithiasis. J Urol 1998; 160: 2284–88.
  • 23. Clark DL, Connors BA, Evan AP, Handa RK, Gao S. Effect of shock wave number on renal oxidative stress and inflammation. BJU Int 2011; 107: 318–22.
  • 24. Greenberg JH, Whitlock R, Zhang WR et al. Interleukin-6 and Interleukin-10 as Acute Kidney Injury Biomarkers after Pediatric Cardiac Surgery Pediatr Nephrol. 2015; 30: 1519–27.
  • 25. de Vries DK, Lindeman JH, Tsikas D et al. Early Renal Ischemia-Reperfusion Injury in Humans Is Dominated by IL-6 Release from the allograft. American Journal of Transplantation 2009; 9: 1574–84.
  • 26. Topsakal C, Kilic N, Ozveren F et al. Effects of prostaglandin E1, melatonin, and oxytetracycline on lipid peroxidation, antioxidant defense system, paraoxonase (PON1) activities, and homocysteine levels in an animal model of spinal cord injury. Spine (Phila Pa 1976) 2003; 28: 1643.
  • 27. Gur M, Aslan M, Yildiz A et al. Paraoxonase and aryl esterase activities in coronary artery disease. Eur J Clin Invest 2006; 36: 779–87.
  • 28. Abraham P, Sugumar E. Enhanced PON1 activity in the kidneys of cyclophosphamide treated rats may play a protective role as an antioxidant against cyclophosphamide induced oxidative stres Arch Toxicol 2008; 82: 237–38.

SWL tedavisi alan hastalarda böbrek hasarının değerlendirilmesinde özel markırlar: TAS, TOS, PON ve IL-6

Yıl 2018, Cilt: 9 Sayı: 3, 173 - 178, 30.09.2018
https://doi.org/10.18663/tjcl.432886

Öz

Amaç: Şok
dalga litotripsi (SWL) prosedürünün böbrek taşları üzerine açık etkinliğinin
yanı sıra böbrekler üzerindeki olumsuz etkileri, oksidan/antioksidan denge ile
ilişkisi ve bu olumsuz etkinin saptanması için biyomarkır arayışları son
yıllarda ilgi çekmektedir. Bu çalışmanın amacı böbrek taşı nedeniyle SWL
tedavisi uygulanan hastalarda erken dönemde böbrek hasarı/travma
belirlenmesinde biyomarkır olarak toplam antioksidan status (TAS), toplam
oksidan status (TOS), oksidatif stres indeksi (OSI), Paraoksonaz-1 (PON-1) ve
Interlökin-6 (IL-6) parametrelerinin olası kullanımını araştırmaktır.

Gereç ve Yöntemler: Böbrek
taşları nedeniyle SWL tedavisi alan 40 hasta işlemden önce ve 2 saat sonra kan
örnekleri toplanarak çalışmaya dahil edildiler.

Bulgular: SWL
tedavisinin oksidan/antioksidan dengesini, IL-6 artışı (P <0,01) ve PON-1
azalması (P = 0.049) ile oksidan parametreler yönünde bozduğu belirlenmiştir. TAS
(P = 0.178), TOS (P = 0.175) ve OSI (P = 0.551) parametrelerinde herhangi bir
değişiklik gözlenmemiştir.







Sonuç: IL-6
ve PON-1'in SWL sonrası erken dönemde renal hasarın belirlenmesinde daha hassas
belirteçler olabileceği gösterilmiştir.

Kaynakça

  • 1. Silay MS, Ellison JS, Tailly T, Caione P. Update on Urinary Stones in Children: Current and Future Concepts in Surgical Treatment and Shockwave Lithotripsy. Eur Urol Focus. 2017; 9: 2405-4569.
  • 2. Rajiv G, Deepak D, Naval K et al. Does the type of steinstrasse predict the outcome of expectant therapy? Indian J Urol 2006; 22: 135.
  • 3. Platonov MA, Gillis AM, Kavanagh KM. Pacemakers, implantable cardioverter/defibrillators, and extracorporeal shockwave lithotripsy: evidence-based guidelines for the modern era. J Endourol 2008; 22: 243.
  • 4. Aksoy H, Aksoy Y, Turhan H, Keleş S, Ziypak T, Ozbey I. The effect of shock wave lithotripsy on nitric oxide and malondialdehyde levels in plasma and urine samples. Cell Biochem Funct 2007; 25: 533–36.
  • 5. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 2004; 286: 431-44.
  • 6. Dundar M, Kocak I, Yenisey C, Serter M, Ozeren B. Urinary and serum cytokine levels in patients undergoing SWL. BJU 2001; 27: 495–99.
  • 7. Chawla LS, Seneff MG, Nelson DR, Williams M, Levy H, Kimmel PL. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol 2007; 2: 22-30.
  • 8. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: The hunt goes on. Biochemical Pharmacology 2011; 81: 337-44.
  • 9. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112–19.
  • 10. Barbosa PV, Makhlouf AA, Thorner D, Ugarte R, Monga M. Shockwave lithotripsy is associated with a higher prevalence of hypertension. Urology. 2011; 78: 22-25.
  • 11. Fischer C, Wöhrle J, Pastor J, Morgenroth K, Senge T. Extracorporeal shockwave lithotripsy induced ultrastructural changes to the renal parenchyma under aspirin use. Electron microscopic findings in the rat kidney. Urologea 2007; 46: 150–55.
  • 12. Lingeman JE, Woods J, Toth PD, Evan AP, McAteer JA. The role of lithotripsy and its side effects. J Urol 1989; 141: 793–77.
  • 13. Clark DL, Connors BA, Evan AP, Willis LR, Handa RK, Gao S. Localization of renal oxidative stress and inflammatory response after lithotripsy. BJU Int 2009; 103: 1562–68.
  • 14. Li X, He D, Zhang L, Cheng X, Sheng B, Luo Y. A novel antioxidant agent, astragalosides, prevents shock wave-induced renal oxidative injury in rabbits. Urol Res 2006; 34: 277–82.
  • 15. Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 503–8.
  • 16. Tappel AI. Lipid Peroxidation damage to cell components. J Fed Proc 1993; 32: 1870-74.
  • 17. Yilmaz E, Haciislamoglu A, Kisa U, Dogan O, Yuvanc E, Batislam E. Ways in which SWL affects oxidant/antioxidant balance. Urolithiasis 2013; 41: 137-41.
  • 18. Goktas C ,Coskun A, Bicik Z et al. Evaluating ESWL-induced renal injury based on urinary TNF-α, IL-1α, and IL-6 levels Urol Res 2012; 40: 569–73.
  • 19. Nakazawa H, Genka C, Fujishima M. Pathological aspects of active oxygens/free radicals. Jpn J Physiol 1996; 46: 15–32.
  • 20. Dennen P, Altmann C, Kaufman J et al. Urine interleukin-6 is an early biomarker of acute kidney injury in children undergoing cardiac surgery Critical Care 2010; 14: 181.
  • 21. Rieder JM, Nisbet AA, Lesser T et al. IL-6 does not predict current urolithiasis in stone formers. J Endourol 2008; 22: 2373–75.
  • 22. Rhee E, Santiago L, Park E, Lad P, Bellman GC. Urinary IL-6 is elevated in patients with urolithiasis. J Urol 1998; 160: 2284–88.
  • 23. Clark DL, Connors BA, Evan AP, Handa RK, Gao S. Effect of shock wave number on renal oxidative stress and inflammation. BJU Int 2011; 107: 318–22.
  • 24. Greenberg JH, Whitlock R, Zhang WR et al. Interleukin-6 and Interleukin-10 as Acute Kidney Injury Biomarkers after Pediatric Cardiac Surgery Pediatr Nephrol. 2015; 30: 1519–27.
  • 25. de Vries DK, Lindeman JH, Tsikas D et al. Early Renal Ischemia-Reperfusion Injury in Humans Is Dominated by IL-6 Release from the allograft. American Journal of Transplantation 2009; 9: 1574–84.
  • 26. Topsakal C, Kilic N, Ozveren F et al. Effects of prostaglandin E1, melatonin, and oxytetracycline on lipid peroxidation, antioxidant defense system, paraoxonase (PON1) activities, and homocysteine levels in an animal model of spinal cord injury. Spine (Phila Pa 1976) 2003; 28: 1643.
  • 27. Gur M, Aslan M, Yildiz A et al. Paraoxonase and aryl esterase activities in coronary artery disease. Eur J Clin Invest 2006; 36: 779–87.
  • 28. Abraham P, Sugumar E. Enhanced PON1 activity in the kidneys of cyclophosphamide treated rats may play a protective role as an antioxidant against cyclophosphamide induced oxidative stres Arch Toxicol 2008; 82: 237–38.
Toplam 28 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Özgün Makale
Yazarlar

Ercan Yuvanc

Devrim Tuglu

Serhan Gur Bu kişi benim

Tunc Ozan

Üçler Kısa

Ertan Batislam Bu kişi benim

Erdal Yılmaz

Yayımlanma Tarihi 30 Eylül 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 9 Sayı: 3

Kaynak Göster

APA Yuvanc, E., Tuglu, D., Gur, S., Ozan, T., vd. (2018). Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment. Turkish Journal of Clinics and Laboratory, 9(3), 173-178. https://doi.org/10.18663/tjcl.432886
AMA Yuvanc E, Tuglu D, Gur S, Ozan T, Kısa Ü, Batislam E, Yılmaz E. Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment. TJCL. Eylül 2018;9(3):173-178. doi:10.18663/tjcl.432886
Chicago Yuvanc, Ercan, Devrim Tuglu, Serhan Gur, Tunc Ozan, Üçler Kısa, Ertan Batislam, ve Erdal Yılmaz. “Clinical Use of Specific Markers TAS, TOS, PON and IL-6 by the Evaluation of Kidney Damage in Patients Receiving SWL Treatment”. Turkish Journal of Clinics and Laboratory 9, sy. 3 (Eylül 2018): 173-78. https://doi.org/10.18663/tjcl.432886.
EndNote Yuvanc E, Tuglu D, Gur S, Ozan T, Kısa Ü, Batislam E, Yılmaz E (01 Eylül 2018) Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment. Turkish Journal of Clinics and Laboratory 9 3 173–178.
IEEE E. Yuvanc, “Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment”, TJCL, c. 9, sy. 3, ss. 173–178, 2018, doi: 10.18663/tjcl.432886.
ISNAD Yuvanc, Ercan vd. “Clinical Use of Specific Markers TAS, TOS, PON and IL-6 by the Evaluation of Kidney Damage in Patients Receiving SWL Treatment”. Turkish Journal of Clinics and Laboratory 9/3 (Eylül 2018), 173-178. https://doi.org/10.18663/tjcl.432886.
JAMA Yuvanc E, Tuglu D, Gur S, Ozan T, Kısa Ü, Batislam E, Yılmaz E. Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment. TJCL. 2018;9:173–178.
MLA Yuvanc, Ercan vd. “Clinical Use of Specific Markers TAS, TOS, PON and IL-6 by the Evaluation of Kidney Damage in Patients Receiving SWL Treatment”. Turkish Journal of Clinics and Laboratory, c. 9, sy. 3, 2018, ss. 173-8, doi:10.18663/tjcl.432886.
Vancouver Yuvanc E, Tuglu D, Gur S, Ozan T, Kısa Ü, Batislam E, Yılmaz E. Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment. TJCL. 2018;9(3):173-8.


e-ISSN: 2149-8296

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.